Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1 Antibody”

1,065 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,065 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07644208
What this trial is testing

PD-1/IL-2 Bispecific Antibody as Neoadjuvant Therapy for Early Recurrent Hepatocellular Carcinoma After Curative Hepatectomy

Who this might be right for
Hepatocellular Carcinoma (HCC)
Shanghai Zhongshan Hospital 30
Testing effectiveness (Phase 2)UnknownNCT06235918
What this trial is testing

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

Who this might be right for
Head and Neck Squamous Cell CarcinomasResectable Head and Neck Squamous-cell Carcinoma
Xiang Lu 30
Testing effectiveness (Phase 2)Study completedNCT02335918
What this trial is testing

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Who this might be right for
Squamous Cell Carcinoma of the Head and Neck (SCCHN)Ovarian Carcinoma-Enrollment CompletedColorectal Cancer (CRC)-Enrollment Completed+2 more
Celldex Therapeutics 175
Early research (Phase 1)Study completedNCT05277402
What this trial is testing

ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Who this might be right for
Advanced/Metastatic Solid Tumors
Adagene Inc 6
Testing effectiveness (Phase 2)Study completedNCT03878472
What this trial is testing

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

Who this might be right for
Gastric Cancer
Qilu Hospital of Shandong University 25
Early research (Phase 1)Ended earlyNCT05061537
What this trial is testing

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Who this might be right for
Renal Cell CancerMelanomaNon-Small-Cell Lung Cancer+7 more
Pfizer 13
Not applicableLooking for participantsNCT05713994
What this trial is testing

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma Non-resectable
Ze-yang Ding, MD 300
Early research (Phase 1)Not Yet RecruitingNCT07637786
What this trial is testing

Peptide Nanovaccine (ONVAX-01) Plus Anti-PD-1 Antibody and Chemotherapy in Advanced Pancreatic Cancer

Who this might be right for
Advanced Pancreatic Adenocarcinoma
Sichuan University 9
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06586294
What this trial is testing

Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Akeso 294
Early research (Phase 1)Study completedNCT01656642
What this trial is testing

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Genentech, Inc. 67
Not applicableLooking for participantsNCT06550921
What this trial is testing

Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma

Who this might be right for
Advanced Hepatocellular CarcinomaOligometastasisAblation+2 more
Sun Yat-sen University 60
Not applicableUnknownNCT05201729
What this trial is testing

Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer

Who this might be right for
Pancreatic Ductal Adenocarcinoma, PDAC
Ruijin Hospital 30
Testing effectiveness (Phase 2)Study completedNCT03304639
What this trial is testing

Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma

Who this might be right for
Advanced Merkel Cell CarcinomaClinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8+5 more
National Cancer Institute (NCI) 9
Testing effectiveness (Phase 2)WithdrawnNCT05039736
What this trial is testing

A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy

Who this might be right for
Hepatocellular CarcinomaLiver Cancer
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Temporarily pausedNCT03779100
What this trial is testing

Lenvatinib Plus PD-1 Antibody for Unresectable ICC

Who this might be right for
Intrahepatic Cholangiocarcinoma
Shi Ming 25
Large-scale testing (Phase 3)Study completedNCT03134872
What this trial is testing

SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+6 more
Jiangsu HengRui Medicine Co., Ltd. 419
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07474064
What this trial is testing

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Who this might be right for
Muscle Invasive Bladder Cancer (MIBC)
chenxu 146
Early research (Phase 1)Study completedNCT02383212
What this trial is testing

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

Who this might be right for
Advanced CancerAdvanced Malignancies
Regeneron Pharmaceuticals 398
Testing effectiveness (Phase 2)Looking for participantsNCT06827236
What this trial is testing

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Who this might be right for
Locally Advanced Breast CancerUnresectable Breast CarcinomaMetastatic Breast Cancer
BioNTech SE 380
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06946836
What this trial is testing

Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study

Who this might be right for
Resectable Non-small Cell Lung CancerBispecific AntibodyNeoadjuvant Therapy
Shanghai Pulmonary Hospital, Shanghai, China 80
Next Page